Navigation Links
Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
Date:8/21/2012

FARMINGTON, Conn., Aug. 21, 2012 /PRNewswire-iReach/ -- Epigenomics is a potential game-changer in the clinical therapeutics and testing markets. From understanding the exosomes involved in the cell migrations characteristic of cancer metastasis to analyzing microRNA expressions, the inception of epigenomics represents a profound intellectual shift in the field of biological investigation. A series of new biotechnology research reports reveal the significant role epigenomics will play in the expanding landscape of tumors and prevailing chronic diseases.

(Photo: http://photos.prnewswire.com/prnh/20120821/CG60595)

Epigenomics, Present and Future Applications for Pharmaceutical and Diganostics

Epigenomics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. This presents significant opportunities for understanding disease processes and developing the means of combating them. The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised. This report looks at the science behind epigenomics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies.

The report strives to predict the potential for epigenomics while reminding market-watchers of the challenges and possible limiting factors in this market. The study of epigenomics today finds itself at a turning point, with many unanswered questions and a proliferation of opportunities for products based on the constant flow of new research findings. This report is essential for pharmaceutical and diagnostic marketers looking to develop future business plans and determine opportunities in a promising field.

An Executive Summary, table of contents, and free sample are available from GII at http://www.giiresearch.com/report/kl248850-epigenomics-present-future-applications.html

Cell Migration Assays Trends 2012

HTStec's industry-wide global web-based benchmarking survey aims to comprehensively document and understand current use of cell migration, motility or invasion assays. The survey also examined the application requirements, market opportunities, metrics, costs, unmet needs and demand for such assays. Equal emphasis was given to soliciting opinion from all areas and organizations were cell migration assays were being deployed. The report is based on 130 responses, from persons or groups undertaking cell migration assays and using or planning to use assay kits or related products.

An Executive Summary, table of contents, and free sample are available from GII at http://www.giiresearch.com/report/hts248381-cell-migration-assays-trends.html

microRNAs and Exosomes Market Report 2012

The focus of this field is moving from basic research towards the utility of associations of microRNA expression patterns in disease. In this manner, microRNA signatures may be validated as biomarkers in many disease areas - cancers, cardiovascular disease, neurological disease, inflammation, and metabolic diseases. Select Biosciences has characterized the associations of microRNAs in various disease classes and presents these detailed associations as "hotspot maps" in this report. Specifically, these associations [to be interpreted as starting material for biomarker development and validation] are described for many cancer classes, cardiovascular disease, CNS disease, diabetes, inflammation, and obesity. They offer the opportunity for R&D planning efforts addressing the question of "which microRNA content needs to be addressed in a particular disease class."

This data-driven characterization of the microRNAs and Exosomes landscape is a hands-on document that can be used for competitive benchmarking, business planning, and strategy development.

An Executive Summary, table of contents, and free sample are available from GII at http://www.giiresearch.com/report/sb248301-micrornas-exosomes-market-report.html

Global Biobanking Market 2011 – 2015

The Global Biobanking market is forecast to grow at a CAGR of 5.5 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant increasing prevalence of chronic diseases. The Global Biobanking market has also been witnessing the trend of an increasing number of mergers and acquisitions among vendors. However, the lack of standardized and high-quality human biospecimens could pose a challenge to the growth of this market.

Key questions answered in this report:

·         What will the market size be in 2015 and at what rate will it grow?
·         What key trends is this market subject to?
·         What is driving this market?
·         What are the challenges to market growth?
·         Who are the key vendors in this market space?
·         What are the opportunities and threats faced by each of these key vendors?
·         What are the strengths and weaknesses of each of these key vendors?

An Executive Summary, table of contents, and free sample are available from GII at http://www.giiresearch.com/report/infi248654-global-biobanking-market.html

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
2. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
3. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
4. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
5. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
6. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
7. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
8. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
9. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
10. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
11. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):